Initiator Pharma A/S
INIT.ST - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$162.23M
Close$
$0.57
72.5% downside
Current Fair Value
72.5% downsideOvervalued by 72.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $162.23 Million |
|---|---|
| Enterprise Value | $154.82 Million |
| Earnings per Share | $-0.23 |
| Beta | 0.1 |
| Outstanding Shares | 68,452,892 |
Return
| Return on Equity | -328.32% |
|---|---|
| Return on Assets | -133.73% |
| Return on Invested Capital | -175.60% |
Valuation & Multiples
| P/E Ratio | -3.96 |
|---|---|
| PEG | -2.72 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.84 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 1.14 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 20, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Initiator Pharma A/S
1 employees
CEO: Claus Elsborg Olesen
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several c...